52 results about "Capsular contracture" patented technology

A biodegradable, flexible covering for a breast implant is provided which comprises one or more biodegradable polymer layers dimensioned and shaped to cover at least a portion of the breast implant. The implant can be inserted into an opening of the covering immediately prior to surgery, but alternate configurations and times of insertion are contemplated as well as open or sheet type devices. The coverings can optionally contain one or more drugs for delivery at the surgical site, particularly for treating or preventing infection, pain, inflammation, capsular contracture, scarring or other complications associated with breast augmentation or breast reconstruction.

A medical implant assembly and method having a medical implant, e.g. a breast prostheses, affixed to a biological interface. The biological interface is comprised of a dermal material with capsular contracture inhibiting properties so that once the medical assembly is inserted into the host, the biological interface, which is intimately coupled to the implant, prevents/reduces capsular contracture formation around the implant.

Disclosed herein are polyurethane polymer matrices with a porosity of from about 20 microns to about 90 microns that are useful in promoting closure and protection of incision sites; supporting the lower pole position of breast implants; and providing a partial or complete covering of breast implants to provide a beneficial interface with host tissue and to reduce the potential for malpositioning or capsular contracture. The disclosed matrices can be seeded with mammalian cells.

A biodegradable cover or coating for a breast implant includes a biodegradable cover or coating over the breast implant and contains one or more drugs for delivery at the surgical site, particularly for treating or preventing infection, pain, inflammation, capsular contracture, scarring or other indication or complication associated with breast augmentation or breast reconstruction.

A medical implant assembly and method having a medical implant, e.g. a breast prostheses, attached to a biological interface. The biological interface is comprised of a dermal material with capsular contracture inhibiting properties so that once the medical assembly is inserted into the host, the biological interface, which is intimately coupled to the implant, prevents/reduces capsular contracture formation around the implant. The biological interface comprises a plurality of apertures along its periphery, and attaches to the medical implant by receiving a plurality of attachment flaps or appendages located on the exterior surface of the medical implant within or through the apertures. The attachment of the biological interface is such that the assembly remains intact even where the attachment flaps loosen upon expansion of the implant after insertion into a host, as where the implant is therein injected to a desired dimension.

Disclosed are an artificial breast implant in which the surface thereof is formed or modified with a silicone open cell (open pore) foam layer, and a method for producing the same. More specifically, disclosed are an artificial breast implant that has a surface including an open cell foam layer made of silicone and thus minimizes side effects such as in vivo rejection, which may occur after implantation of the implant into the body, in particular, the occurrence of capsular contracture to achieve superior biocompatibility and safety, and a method for producing the same.

The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and/or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-α and anti-TGF-β1 action for the treatment of hepatic fibrosis.

The invention relates to application of captopril to the preparation of medicaments for treating and/or inhibiting scar hyperplastic diseases. Particularly, the hyperplastic diseases comprise hyperplastic scar, cheloid, urethral scar stricture and silicon gel breast augmentation prosthesis postoperative capsular contracture. When the diseases are treated, the captopril is used as an active ingredient, clinically-used emulsifiable paste, gel, injection and the like in different formulations are prepared by the conventional preparation process. The study indicates that the captopril can reduce the capacity of synthesizing pathologic scar fibroblast collagen and secreting the collagen, weaken the multiplication capacity of fibroblasts and reduce the expression of transforming growth factor-beta 1 (TGF-beta 1), and has a good treatment or prevention effect on pathologic scars. Simultaneously, the captopril acts on scar tissue directly, has the advantages of small dose, high curative effect, small side effect, mature raw material process, readily available materials, low cost and the like, and is expected to become a main medicament for treating and preventing the scars clinically.

Methods for prevention or treatment of capsular contracture following surgical implants and other fibrosis related conditions comprising applying a topical composition comprising a pharmaceutically acceptable keratolytic, a pharmaceutically acceptable protein denaturant, a hydrating agent, and combinations thereof are disclosed.

A device for exerting a compression force on a breast implant located within a user's breast. The device includes a support member adjustably connect to a compression member, the compression member comprising a positioning element on one side of the compression member such that the positioning element is aligned with medial side of the breast and a compression element on the second side of the compression member such that the compression element is positioned on lateral side of the breast, and means extending between the positioning element and the compressing element for retaining the positioning element and the compressing element on opposite sides of the breast, and means for providing pressure to the compressing element causing the compressing element to apply a compression force to the breast implant within the user's breast. Additionally a method for preventing capsular contracture after breast implant surgery is provided.

The invention discloses a primary biplanar mammary augumentation method. The method comprises the following steps: formulation of an operation plane; preparation of breast prosthesis: preparing the breast prosthesis by a 3D printing technology according to various parameters of the breasts of a patient; preoperative preparation; cutting: cutting the breasts according to cuts designed before operation under armpits with a width smaller than 3 cm, perfectly fusing scar with armpit folds to realize traceless conceal; gap separation; breast prosthesis implantation; suturing: suturing the cuts withmedical suture and adopting a pressurized fixed binding manner; and postoperative nursing. According to the biplanar method, after the lower side of pectoralis major is divided, the risk of upward and outward shift of the prosthesis is reduced, the prosthesis deformation caused by contraction of the pectoralis major is also effectively reduced, after part of prosthesis is placed behind the pectoralis major by the biplanar method, the probability of infection and capsular contracture is reduced, the position of lower plica after mammary augumentation can be accurately controlled by the biplanar mammary augumentation operation, the postoperative effect is stable, and shift cannot be caused easily.